Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026
Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Fineline Cube Feb 3, 2026
Company Deals

WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases

Fineline Cube Feb 3, 2026
Company Deals

Zenshine Pharma Files for Hong Kong IPO with $357M Valuation

Fineline Cube Feb 2, 2026
Company Deals

Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia

Fineline Cube Feb 2, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Fineline Cube Feb 3, 2026
Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Fineline Cube Feb 3, 2026
Company Drug

Jiangsu Hengrui and Chongqing Genrix Launch Anti-IL-17 Therapies for Psoriasis in China

Fineline Cube Sep 4, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) and Chongqing Genrix Biopharmaceutical Co., Ltd, two leading...

Policy / Regulatory

China Unveils Blueprint for Service Trade Expansion through Strategic Opening Up

Fineline Cube Sep 4, 2024

China’s State Council has issued a strategic directive titled “Opinions on Promoting the High-quality Development...

Policy / Regulatory

China’s NHC Charts Ambitious Healthcare Reform Path with Emphasis on TCM and Technology

Fineline Cube Sep 4, 2024

Lei Haichao, Director of China’s National Health Commission (NHC), has outlined a comprehensive reform agenda...

Company Deals

EpimAb’s EMB-06 Secures $635 Million Licensing Agreement with Vignette for Multiple Myeloma Therapy

Fineline Cube Sep 4, 2024

EpimAb Biotherapeutics, a Shanghai-based biotech firm, has inked a licensing deal with Vignette for the...

Company Drug

Sanofi’s Tolebrutinib Shows Mixed Results in Phase III Multiple Sclerosis Trials

Fineline Cube Sep 3, 2024

PARIS—French pharmaceutical giant Sanofi (NASDAQ: SNY) has reported mixed outcomes from three Phase III trials...

Company Drug

Bayer’s Finerenone Shows Promise in Heart Failure Treatment, Outperforms Placebo in Phase III Trial

Fineline Cube Sep 3, 2024

FRANKFURT—Bayer AG (FRA: BAYN) has announced positive results from the Phase III FINEARTS-HF study for...

Company Drug

Henlius Biotech’s HLX17 Biosimilar to MSD’s Keytruda Wins NMPA Clinical Trial Approval

Fineline Cube Sep 3, 2024

SHANGHAI—Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clinical trial approval...

Company Drug

Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablet Earns FDA Breakthrough Therapy Designation for Stroke Treatment

Fineline Cube Sep 3, 2024

HONG KONG—Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received Breakthrough...

Company Deals

Jiangsu Simcere Acquires Exclusive Rights to TargetRx’s TGRX-326 in Licensing Deal

Fineline Cube Sep 3, 2024

SHENZHEN—Shenzhen TargetRx, Inc., a leading developer of small-molecule kinase inhibitors, has entered into a licensing...

Company Drug

GeneQuantum Healthcare’s GQ1005 ADC Receives CDE Clearance for Phase III Breast Cancer Trial

Fineline Cube Sep 3, 2024

SUZHOU—GeneQuantum Healthcare (Suzhou) Co., Ltd has received clearance from the Center for Drug Evaluation (CDE)...

Company Medical Device

Beijing Balance Medical Secures NMPA Nod for Renatus Transcatheter Aortic Valve System

Fineline Cube Sep 3, 2024

BEIJING—Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has received market approval from the National...

Company Drug

Sinocelltech’s Anti-Angiogenic Biologic SCT520FF Gets NMPA Green Light for Neovascular AMD Clinical Study

Fineline Cube Sep 3, 2024

SHANGHAI—Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that it has received...

Company Deals

Zhejiang Dian Diagnostics Partners with Shanghai Mycology Lab to Advance Fungal Infection Diagnostics

Fineline Cube Sep 3, 2024

SHANGHAI—Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading player in the diagnostics industry, has...

Company Deals

Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024

Fineline Cube Sep 3, 2024

SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...

Company Drug

China’s Evopoint Biosciences and UK’s GSK Eye Breakthrough Therapy Designations for Cancer Therapies

Fineline Cube Sep 3, 2024

BEIJING/LONDON—The Center for Drug Evaluation (CDE) in China has indicated that Evopoint Biosciences’ EZH2 inhibitor...

Company Deals

Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials

Fineline Cube Sep 3, 2024

HONG KONG—Duality Biologics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is...

Company

MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1

Fineline Cube Sep 3, 2024

SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...

Company Drug

Shandong Buchang Pharmaceuticals’ rhEPO-Fc for CKD Anemia Accepted for Review by China’s CDE

Fineline Cube Sep 3, 2024

BEIJING—The Center for Drug Evaluation (CDE) in China has accepted the market filing for a...

Company Drug

Biocon Biologics Resolves Patent Dispute with J&J, Secures Market Entry for Biosimilar Stelara

Fineline Cube Sep 2, 2024

Biocon Biologics Ltd, the biosimilars division of Indian pharmaceutical company Biocon Ltd (BOM: 532523, NSE:...

Company Drug

Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan

Fineline Cube Sep 2, 2024

Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US...

Posts pagination

1 … 255 256 257 … 618

Recent updates

  • Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation
  • Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China
  • SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal
  • Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership
  • Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.